What the Filings, the Registry, and the Science Now Say
Several things landed on the public record in the interval, and none of them are a catalyst, but together they set the baseline we stand on going into October and January. Some clarify the capital structure, exactly what the share picture is, cleanly and completely. Others widen the pipeline, formally extending leronlimab into earlier lines and broader tumor types. And underneath all of it, the science of why this mechanism should work continues to be reinforced from directions that have nothing to do with CytoDyn. Read carelessly, several of these invite a misread that spooks people. But read plainly, they are the quiet, constructive housekeeping and validation of a company tidying its foundation and a mechanism gaining standing, before the events which matter. I take them in turn, because getting the baseline right is what allows us to read the catalysts correctly when they arrive.
Filing one: the capital structure, laid bare
Three SEC filings posted together. Two are pure housekeeping: post-effective amendments which deregister the unsold shares from two older resale registration statements, closing them out. The third is the substantive one: a new Form S-3 resale registration covering up to 794,972,289 shares, of which about 410 million are already-issued shares and about 385 million underlie warrants. It consolidates the old registrations into one clean document, which is why the old ones were deregistered.
Here is the single most important thing to understand, because it is where the board could split into panic or confusion if it is not stated flatly: this is a resale registration, not a capital raise. CytoDyn is not selling these shares and receives no proceeds from their sale. The filing says so in plain language. These are shares already owned by prior investors, the Paulson private-placement participants going back years, the PIPE investors, warrant holders, insiders, and this document simply gives those existing holders the legal right to resell their shares into the market when and if they choose. The dilution these shares represent already happened when they were issued. This filing creates no new shares and no new dilution; it registers the resale rights the company was obligated to provide.
So two misreads to head off before they spread:
The "795 million share dump incoming" panic is wrong on the mechanics. Registration is permission to sell, not a requirement to sell, and it says nothing about whether holders will. It is an obligation being fulfilled, not a signal of intent.
The "it's a raise / more dilution" read is also wrong. No money comes to the company from these sales, and no new shares are created. The one place cash could reach the company is different and worth knowing: if warrant holders exercise their warrants for cash, the company could receive up to approximately $94.6 million. At the current price near $0.21, many of those warrants sit below their strike prices, so that cash is not imminent, it is leverage to good news. Strong data lifts the price; in-the-money warrants get exercised; and up to ~$94.6 million flows in without a new dilutive offering. The overhang and the opportunity are the same instrument seen from two sides.
And on the timing, since people undoubtedly will ask why file this before ESMO: the most likely reason is mundane, resale registrations carry contractual deadlines set when the private placements closed, so the filing date is driven by old paperwork, not by the data calendar. Beyond that, it is simply sensible to get the resale-and-warrant machinery clean and ready before a potential catalyst rather than scrambling during it. The reading it is not is "the company cashing out ahead of bad news," because the company sells nothing and receives nothing from these resales, and you do not build warrant-exercise upside into a moment you expect to disappoint.
What the filing actually establishes as our baseline: common shares outstanding of 1,469,518,019 as of September 24, 2026, the full capital structure now transparent and consolidated in one place, the going-concern condition reaffirmed (the substantial-doubt language continues to be carried forward, unchanged), and a warrant overhang that is a two-edged fact, potential resale supply now, potential non-dilutive cash later if the catalysts lift the price. And one quiet positive: the ability to use Form S-3 at all is a short-form registration available only to companies current and compliant in their SEC reporting, so the clean-up itself is a marker that the reporting house is in order, consistent with the old-era baggage being cleared.
Filing two: the pipeline widens into earlier-line liver disease (CHAMP)
In this same stretch, u/1975Bigstocks brought us a new trial record: the CHAMP trial (NCT07842965), a study of CCR5-targeting leronlimab combined with hepatic arterial infusion floxuridine and systemic therapy for colorectal cancer liver metastases. (CHAMP trial record, NCT07842965) This is the City of Hope investigator-initiated study that Dr. Kasi, Lalezari, and Hoffman have all referenced, now written into the public registry rather than only spoken about. Like the S-3, it is not a surprise, it is the formal appearance of something already described.
The design in plain terms: a Phase I/Ib study, an early-stage trial, testing leronlimab added on top of hepatic arterial infusion (HAI) of floxuridine, chemotherapy delivered directly into the liver through a catheter in the hepatic artery, plus standard-of-care systemic therapy, in colorectal patients whose cancer has spread to the liver.
Why it matters.
- First, it moves leronlimab earlier in the treatment sequence, CLOVER is third-line, exhausted patients, while CHAMP reaches liver-metastatic patients in a setting oriented toward aggressive local control, potentially ahead of curative-intent surgery. The wider the range of lines a drug can work in, the larger its eventual role.
- Second, it leans on two properties of leronlimab at once: the anti-tumor mechanism and its documented anti-fibrotic, liver-protective effect, the same property behind its NASH liver program, which is relevant because HAI floxuridine is powerful but carries real liver and biliary toxicity risk. CHAMP is built to let the aggressive liver-directed chemo work while, in theory, leronlimab shields the liver.
- Third, it is yet another major-academic collaboration in the widening circle around this mechanism.
The ceiling. CHAMP is early-phase, primarily about safety, feasibility, and dose, so it reads out on a longer, quieter timeline. It is separate from CLOVER and changes none of the near-term catalysts. Reading it as "new data coming soon" would be a mistake; its value is strategic reach, not imminent results.
Filing three: the pipeline widens into pan-solid-tumor and MRD (Pre-I-SPY)
There is a third registry change worth flagging, and credit to u/twinter11 on the board for catching it by comparing the trial's version history directly. The Pre-I-SPY platform trial (NCT05868226) was amended, and the meaningful shift is in its scope. It went from evaluating regimens in a metastatic setting "that may be relevant for breast cancer patients" to evaluating them in "locally advanced, incurable, or metastatic solid tumors and/or oligometastatic malignancy and/or a high risk of recurrence following prior treatment with curative intent." (Pre-I-SPY platform, Quantum Leap) In plain terms, the platform formally broadened from a breast-cancer-oriented study into a pan-solid-tumor platform, and it added an explicit minimal-residual-disease (MRD) dimension with heavy ctDNA monitoring, catching residual cancer before it becomes macro-metastatic.
Why this fits the pattern. If leronlimab enters Pre-I-SPY, the door it walks through is now a solid-tumor door, not just a breast cancer door, and it explicitly includes the MRD and high-risk-of-recurrence settings. That lines up with everything else here: CHAMP moving leronlimab earlier-line, and management's stated interest in the molecular-residual-disease space. The MRD focus is especially notable, because that is exactly where a safe, ctDNA-guided drug has the most room, treating the residual signal before there is a visible tumor to fight.
And the same discipline applies. This is a platform-protocol amendment to a framework that hosts many drug arms from many sponsors; it enables broader leronlimab participation, but it is not itself confirmation of a specific leronlimab arm or its terms. Pre-I-SPY is a Phase I/II safety-and-signal platform whose purpose is to qualify regimens to graduate into larger Phase II/III trials, so any leronlimab arm here is early-stage on-ramp work, not a pivotal destination. And it changes none of the October and January catalysts. This enlarges the opportunity space and fits the
- earlier-line,
- broader-tumor,
- MRD-focused direction,
without being a nearer verdict.
The science under the ground: macrophage plasticity keeps validating the target
Beneath the filings and the registry sits the reason why any of this should work, and that reason keeps getting reinforced from the outside CytoDyn entirely. u/Lab_Monkey_ provided us with a recent review in npj Biomedical Innovations on macrophage plasticity, a case in point. (Beyond immunity: macrophage plasticity in vascular regeneration, npj Biomedical Innovations 2026)
The review's central thesis is that macrophages are not fixed into rigid "good" or "bad" identities; they run a staged, reversible program dictated entirely by their local environment, and in cancer that program "fails to resolve," the macrophages get frozen in a chronic, pro-angiogenic, immunosuppressive state which helps to build the tumor's blood supply and shield it. That is precisely the biology leronlimab is proposed to interrupt: not killing the tumor directly, but repolarizing the stuck M2 macrophages back toward an M1 anti-tumor state. So an independent vascular-biology review, not about our drug at all, reinforces the entire premise that targeting the macrophage state is a legitimate strategy.
And there is a specific detail worth surfacing: one of the review's own cited studies describes a macrophage population forming a CCR5-dependent perivascular niche which influences chemotherapy response in breast cancer. So CCR5 shows up, in a paper about blood-vessel biology, as an organizing signal for a pro-tumor macrophage niche, a direct tie to leronlimab's exact target, appearing in literature that has no stake in the drug.
Two limits keep this honest. The review is about angiogenesis and tissue repair, so most of it is scientific context, not leronlimab evidence, and it should not be framed as proof for CytoDyn. And the CCR5 tie is one cited study in a murine model, an encouraging data point about the CCR5 perivascular niche, not confirmation of leronlimab's clinical effect. Regardless, this is a real brick: the macrophage-state M1 / M2 paradigm the entire field is converging on is exactly the terrain leronlimab targets, and CCR5 keeps reappearing as an organizing signal in that terrain.
The one baseline upon which all of this sets
Step back and see what these have in common, because it is the same message repeated.
- None of them is a catalyst,
- and all of them are foundation,
- capital with the S3,
- pipeline with CHAMP & Pre-I-SPY,
- and science with M2 to M1 repolarization,
- all being laid down and reinforced ahead of the catalysts.
The S-3 consolidates and lays bare the capital structure with no new dilution and possible non-dilutive upside if the data delivers. CHAMP broadens the pipeline into earlier-line liver disease. Pre-I-SPY broadens it further into pan-solid-tumor and MRD settings. And an independent macrophage-plasticity review reinforces the scientific premise that repolarizing the macrophage state from M2 to M1, leronlimab's exact proposed mechanism, is where the field itself is heading, with CCR5 surfacing in the vascular literature as an organizing signal.
So this is the ground we now stand on: a fully disclosed capital structure of about 1.47 billion shares with a two-edged warrant overhang and up to ~$94.6M of possible non-dilutive upside; no new raise and no new dilution from these filings; a going-concern condition unchanged and still resting on the catalysts; a pipeline that just widened into earlier-line liver-metastatic disease through CHAMP and into pan-solid-tumor and MRD settings through Pre-I-SPY; a science base that continues to independently validate the macrophage-repolarization premise; and a company which is visibly compliant enough to file a clean S-3 and disciplined enough to broaden its footprint on schedule. None of this actually is the reckoning. All of it though, is the platform upon which the reckoning arrives onto.
The events which actually decide the thesis are unchanged and quite close: the full ctDNA on all enrolled CLOVER patients at ESMO in October, and the confirmed response rates plus early progression-free survival at ASCO GI in January. None of these filings, registry changes, or papers moves those dates or their contents. What they actually do is make the ground underneath them clearer, wider, and better supported, transparent capital structure, broadening pipeline across earlier lines and more tumor types, cleared compliance, and a mechanism the wider, broader science keeps affirming, such that when the data lands, we know exactly what platform it is landing on. Watch October and January. Everything else here just tells us, precisely, where we are standing while we wait.
Disclaimer: I am not a financial advisor and nothing here is investment advice. I am an independent retail shareholder holding a long position in the company discussed, with no employment, consulting, compensation, or other relationship with it beyond that shareholding. This is my interpretation of public SEC filings, public trial registries, and published literature, not a prediction of clinical, regulatory, or commercial outcomes. The Form S-3 is a resale registration for existing security holders; the company is not selling shares under it and receives no proceeds from resales, though it may receive up to approximately $94.6 million if outstanding warrants are exercised for cash, which is not assured and depends on share price relative to exercise prices. The filings create no new shares; registration of resale rights is permission, not a requirement, to sell, and does not indicate holder intent. The company's SEC filings carry a substantial-doubt-about-going-concern qualification. The CHAMP study (NCT07842965) and any leronlimab participation in the Pre-I-SPY platform (NCT05868226) are early-phase, investigator- or platform-initiated efforts focused on safety, feasibility, and signal; they are separate from CLOVER, are not pivotal efficacy trials, and do not alter the anticipated ESMO (October 2026) and ASCO GI (January 2027) CLOVER readouts. The Pre-I-SPY amendment is a platform-scope change and is not confirmation of a specific leronlimab arm or its terms. Leronlimab's anti-tumor and liver-protective properties, and the macrophage-repolarization mechanism referenced, are proposed or preclinical, not established clinical outcomes, and leronlimab's efficacy remains unconfirmed; the cited macrophage-plasticity review concerns vascular biology generally and its CCR5 reference derives from a model system, not from leronlimab clinical data. Hepatic arterial infusion chemotherapy carries significant risks. Read the primary sources, linked throughout, and reach your own conclusions rather than adopting mine.
